Ljupco Veskovski

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.

M. Beksac, M. Dimopoulos, H. Einsele, 2014, The Lancet. Oncology.

Regional differences in treatment and outcome for myeloma patients in Sweden: A population based Swedish myeloma register study

G. Juliusson, H. Nahi, I. Turesson, 2021, Cancer reports.

Melphalan 100 mg/m2 with stem cell support as first relapse treatment is safe and effective for myeloma patients with long remission after autologous stem cell transplantation

U. Mellqvist, E. Holmberg, J. Westin, 2011, European journal of haematology.

Sequence variation at the MTHFD1L-AKAP12 and FOPNL loci does not influence multiple myeloma survival in Sweden

U. Mellqvist, B. Nilsson, U. Gullberg, 2019, Blood Cancer Journal.

Serum Metabolomic Profiling Correlated with ISS and Clinical Outcome for Multiple Myeloma Patients Treated with High-dose Melphalan and Autologous Stem Cell Transplantation.

U. Mellqvist, D. Malmodin, I. Turesson, 2021, Experimental hematology.